RECORD // Company

Olema Oncology, Inc.

Formerly: Olema Pharmaceuticals, Inc.

Built 2026-11-22T00:33:34Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (6)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Olema Pharmaceuticals Inc · Ca business · same registered legal name as 'Olema Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Olema Pharmaceuticals Inc · Ca business · same registered legal name as 'Olema Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Olema Pharmaceuticals Inc · Ca business · same registered legal name as 'Olema Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Olema Pharmaceuticals Inc · Ca business · same registered legal name as 'Olema Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Olema Pharmaceuticals Inc · Ca business · same registered legal name as 'Olema Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Olema Pharmaceuticals, Inc. · Ctgov · same registered legal name as 'Olema Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-10 · accession 0001193125-26-454421

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-73,599,0003 months ended 2026-09-3010-Q2026-11-100001193125-26-4544212026-11-22 00:33 UTCReport an error
Cash and cash equivalents$47,522,000at 2026-09-3010-Q2026-11-100001193125-26-4544212026-11-22 00:33 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001750284
Ticker
OLMA
EIN
300409740
CUSIP
68062P106
Record ID
sx:sec:0001750284

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

34 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 00:33 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 00:33 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 00:33 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 00:33 UTCReport an error
Business address365 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 940802026-11-16SEC EDGAR company profile2026-11-22 00:33 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 00:33 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-162,451,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:33 UTCReport an error
Total assets (at 2025-12-31)$533,430,0002025-12-3110-K, XBRL Assets2026-11-22 00:33 UTCReport an error
Stockholders' equity (at 2025-12-31)$478,559,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:33 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$48,301,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:33 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-146,716,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:33 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2024-12-31)$159,0002024-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 00:33 UTCReport an error
Operating lease liabilities (at 2025-12-31)$1,193,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 00:33 UTCReport an error
Form D total offering amount (D filed 2024-12-12)$249,999,9862024-12-12D2026-11-22 00:33 UTCReport an error
Form D total amount sold (D filed 2024-12-12)$249,999,2252024-12-12D2026-11-22 00:33 UTCReport an error
Form D industry groupPharmaceuticals2024-12-12D2026-11-22 00:33 UTCReport an error
Form D revenue rangeDecline to Disclose2024-12-12D2026-11-22 00:33 UTCReport an error
Form D date of first sale2024-12-042024-12-12D2026-11-22 00:33 UTCReport an error
8-K Item 5.03, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year (filed 2026-11-12)On November 12, 2026, Olema Oncology, Inc. (formerly known as Olema Pharmaceuticals, Inc.) (the “Company”) filed its Eighth Amended and Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware to change the Company's corporate name from “Olema Pharmaceuticals, Inc.” to “Olema Oncology, Inc.” (the “Name Change”). The Restated Certificate became effective at 4:01 p.m., Eastern Time, on November 12, 2026. The Company's Board of Directors (the “Board”) approved the Restated Certificate in accordance with the Delaware General Corporation Law (“DGCL”). Pursuant to the DGCL, stockholder approval was not required to effect the Name…2026-11-12SEC EDGAR 8-K 0001193125-26-458572 (text as filed, excerpt)2026-11-22 00:33 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-12)On November 12, 2026, the Company issued a press release announcing the Company's name change, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.2026-11-12SEC EDGAR 8-K 0001193125-26-458572 (text as filed, excerpt)2026-11-22 00:33 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-12)Effective November 12, 2026, the Company relocated its principal executive offices from 780 Brannan Street, San Francisco, CA 94103 to 365 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080.2026-11-12SEC EDGAR 8-K 0001193125-26-458572 (text as filed, excerpt)2026-11-22 00:33 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-10)On November 10, 2026, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference. The information in Item 2.02, including the press release attached as Exhibit 99.1 hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by…2026-11-10SEC EDGAR 8-K 0001193125-26-454403 (text as filed, excerpt)2026-11-22 00:33 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-08-13)On August 13, 2026, the Company issued a press release announcing the appointment of Mr. O’Byrne as the Company’s Chief Financial Officer. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.2026-08-13SEC EDGAR 8-K 0001193125-26-347853 (text as filed, excerpt)2026-11-22 00:33 UTCReport an error
Plan (pension, plan no. 001)OLEMA ONCOLOGY 401(K) PLAN: 171 participants, assets $18,427,1062025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-22 00:33 UTCReport an error
Largest institutional holder #1 (13F as filed): FMR LLC$151,909,7022026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #2 (13F as filed): Paradigm Biocapital Advisors LP$108,468,9062026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #3 (13F as filed): Jupiter Topco LLC$88,802,8422026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #4 (13F as filed): Bain Capital Life Sciences Investors, LLC$88,636,4652026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #5 (13F as filed): BlackRock, Inc.$84,000,7832026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #6 (13F as filed): BVF INC/IL$66,251,6212026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #7 (13F as filed): Siren, L.L.C.$60,760,4322026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #8 (13F as filed): STATE STREET CORP$53,993,8862026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #9 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$41,798,6252026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #10 (13F as filed): Logos Global Management LP$40,143,0262026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.